Supplemental Figures 1-6 from Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6

Supplemental figure 1-983BR and 1205LuR are resistant to vemurafenib. Cell cycle analysis of 983B, 983BR, 1205Lu, and 1205LuR cells treated with or without vemurafenib for 2 days by FACS. Supplemental Fig. 2 Inhibition of mTOR signaling pathway is critical for palbociclib-induced senescence in 983BR vemurafenib resistant cells, related to Figure. 6. Supplemental Fig. 3 Overexpression of mTOR signaling overrides palbociclib-induced senescence in 983BR vemurafenib resistant cells, related to Figure. 7. Supplemental Fig. 4 Rb expression in palbociclib resistant cells. Supplemental Fig. 5 Rapamycin negatively regulates geroconversion in esophageal cancer cell lines (referred to in discussion). Supplemental Fig. 6 Palbociclib has no cytotoxicity in 983BR vemurafenib resistant cells.